StreetInsider.com News Articles

Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference

Thu, 30 Jul 2026 16:05:00 -0400

Pulse Biosciences’ Management is scheduled to present on Tuesday, August 11, at 2:30 pm ET. A live and recorded webcast of the fireside chat will be available on the “Events Calendar and Presentations” page of the company’s investor website at http://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation

Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference

Thu, 30 Jul 2026 16:05:00 -0400

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation

Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference

Thu, 30 Jul 2026 16:05:00 -0400

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation

Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference

Thu, 30 Jul 2026 16:05:00 -0400

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation

Form 8-K PULSE BIOSCIENCES, INC. For: Jul 29

Wed, 29 Jul 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260729/26831699.html

Form 8-K PULSE BIOSCIENCES, INC. For: Jul 29

Wed, 29 Jul 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260729/26831699.html

Pulse Biosciences passes enrollment midpoint in atrial fibrillation study

Wed, 29 Jul 2026 07:01:01 -0400

Pulse Biosciences, Inc. (Nasdaq: PLSE) announced that its NANOPULSE-AF pivotal study has surpassed its enrollment midpoint, according to a press release from the company. The study, which uses the company's nanosecond pulsed field ablation technology to treat atrial fibrillation, began enrolling patients in April 2026.

The NANOPULSE-AF study is an Investigational Device Exemption (IDE) pivotal trial evaluating the company's nPulse Cardiac Catheter System for pulmonary vein isolation in patients with atrial fibrillation.

Vivek Reddy, MD, Director of Cardiac Arrhythmia Services at the Mount Sinai Fuster Heart Hospital and National Principal Investigator of the study, cited the ease of use of the catheter

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

Wed, 29 Jul 2026 07:00:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the NANOPULSE-AF Study has surpassed its enrollment midpoint after commencing the study in April 2026.

“We are very pleased by the strong enrollment trajectory in the NANOPULSE-AF study. Reaching this midpoint milestone so quickly reflects the enthusiasm of our investigational sites for this technology and its potential to deliver leading durability in pulmonary vein isolation, procedural efficiency and consistent safe and effective patient outcomes,” said David Kenigsberg, MD, FACC, FHRS, Chief Medical

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

Wed, 29 Jul 2026 07:00:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the NANOPULSE-AF Study has surpassed its enrollment midpoint after commencing the study in April 2026.

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

Wed, 29 Jul 2026 07:00:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the NANOPULSE-AF Study has surpassed its enrollment midpoint after commencing the study in April 2026.

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

Wed, 29 Jul 2026 07:00:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the NANOPULSE-AF Study has surpassed its enrollment midpoint after commencing the study in April 2026.

Pulse Biosciences (PLSE) PT Raised to $35 at Oppenheimer

Tue, 28 Jul 2026 06:05:10 -0400

(Updated - July 28, 2026 6:05 AM EDT)

Oppenheimer analyst Suraj Kalia raised the price target on Pulse Biosciences (NASDAQ: PLSE) to $35.00 (from $30.00) while maintaining a Outperform rating.

The analyst commented: "nsPFA's 90% 1-year Freedom from AF EFS study (note) has shown drastic improvement over ~75% seen with other PFA platforms. Two key questions we have been asked by clients are: 1) What explains the differential efficacy improvement? 2) Can results be replicated in the pivotal? In this note, we highlight a technical nuance that requires consideration . . . the difference in allowable lesion sets between nsPFA EFS and

Pulse Biosciences (PLSE) PT Raised to $35 at Oppenheimer

Tue, 28 Jul 2026 06:05:10 -0400

(Updated - July 28, 2026 6:05 AM EDT)

Oppenheimer analyst Suraj Kalia raised the price target on Pulse Biosciences (NASDAQ: PLSE) to $35.00 (from $30.00) while maintaining a Outperform rating.

Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026

Tue, 21 Jul 2026 16:05:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)--

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates and financial results for the second quarter 2026 after market close on Thursday, August 6, 2026. Company management will host a corresponding conference call to discuss business updates beginning at 1:30pm PT / 4:30pm ET.

Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 from the U.S. or 1-646-307-1963 internationally and providing Conference ID 3486060. A live and recorded webcast of

Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026

Tue, 21 Jul 2026 16:05:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)--

Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026

Tue, 21 Jul 2026 16:05:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)--

Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026

Tue, 21 Jul 2026 16:05:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)--

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 15 Jul 2026 16:05:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on July 13, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

Pulse has awarded inducement options to three new employees to purchase, in aggregate, up

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 15 Jul 2026 16:05:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on July 13, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

Pulse has awarded inducement options to three new employees to purchase, in aggregate, up

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 15 Jul 2026 16:05:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on July 13, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

Pulse has awarded inducement options to three new employees to purchase, in aggregate, up

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 15 Jul 2026 16:05:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on July 13, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

Pulse has awarded inducement options to three new employees to purchase, in aggregate, up

Form 4 PULSE BIOSCIENCES, INC. For: Jun 11 Filed by: Zanganeh Mahkam

Mon, 15 Jun 2026 21:22:00 -0400

si-local-file:///var/storage/secattach/20260615/26649239.html

Form 4 PULSE BIOSCIENCES, INC. For: Jun 11 Filed by: Zanganeh Mahkam

Mon, 15 Jun 2026 21:22:00 -0400

si-local-file:///var/storage/secattach/20260615/26649239.html

Form 4 PULSE BIOSCIENCES, INC. For: Jun 11 Filed by: van den Broek Richard

Mon, 15 Jun 2026 21:07:00 -0400

si-local-file:///var/storage/secattach/20260615/26649215.html

Form 4 PULSE BIOSCIENCES, INC. For: Jun 11 Filed by: van den Broek Richard

Mon, 15 Jun 2026 21:07:00 -0400

si-local-file:///var/storage/secattach/20260615/26649215.html